CDEK
← All drugs Report issue

icotinib

Trade name: Conmana

Small moleculeexperimental

Icotinib is a highly selective, first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Icotinib is approved for use in China as first-line monotherapy in patients with non-small-cell lung cancer with somatic EGFR mutations. — Wikipedia

Clinical trial activity

87 trials · 54 clinical orgs · 0 marketing orgs

Phase 1
8
Phase 2
67
Phase 3
16
Phase 4
11

Earliest trial started Feb 1, 2009 (NCT01040780)

Timeline

2000s

  1. Jan 1, 2009

    Earliest Phase 3 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C#Cc1cccc(Nc2ncnc3cc4c(cc23)OCCOCCOCCO4)c1
Mol. weight
391.43 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 4-((3-ethynylphenyl)amino)-6,7-benzo-12-crown-4-quinazoline
  • bpi-2009
  • bpi-2009
  • icotinib
  • icotinib
  • icotinib
  • icotinib
  • icotinib
  • icotinib hydrochloride
  • icotinib hydrochloride

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT06517953Phase 2Jul 17, 2024Sun Yat-Sen University
NCT06041776Phase 3Mar 28, 2023Betta Pharmaceuticals Co.,Ltd., Jiao Tong University
NCT05514314Phase 2Sep 1, 2022Peking University
NCT05132985Phase 2Jan 1, 2022Dalian Medical University
NCT05104788Phase 2Oct 25, 2021Chinese Academy of Medical Sciences
NCT05263947Phase 3Aug 30, 2021Tianjin Medical University
NCT05007938Phase 2Aug 12, 2021Betta Pharmaceuticals Co.,Ltd., Xiamen University
NCT04797806Phase 3Mar 12, 2021Tianjin Medical University
NCT04206072Phase 2/Phase 3 (Phase 3)Feb 1, 2020Betta Pharmaceuticals Co.,Ltd., Jiao Tong University
NCT04193007Phase 2Dec 1, 2019Nanchang University
NCT03992885Phase 3Jul 1, 2019Tianjin Medical University
NCT03983811N/AJul 1, 2019Southern Medical University
NCT03766490N/AMar 30, 2019Changzhou No.2 People's Hospital, Jiangnan University, Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Jiangyin People's Hospital, Nantong University, Soochow University, The First People's Hospital of Changzhou
NCT03754530Phase 2Dec 1, 2018Betta Pharmaceuticals Co.,Ltd., Fujian Medical University
NCT03749213Phase 2Dec 1, 2018Betta Pharmaceuticals Co.,Ltd., Chinese Academy of Medical Sciences
NCT03736837Phase 2Dec 1, 2018Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd, Tianjin Medical University
NCT03720873Phase 2Oct 31, 2018Fujian Medical University
NCT03349203Phase 2Oct 1, 2018Betta Pharmaceuticals Co.,Ltd., Chinese Academy of Medical Sciences
NCT04058704Phase 3Jul 20, 2018Betta Pharmaceuticals Co.,Ltd., Chinese Academy of Medical Sciences
NCT03396185Phase 2May 9, 2018Betta Pharmaceuticals Co.,Ltd.
Showing 20 of 87 trials
Page 1 / 5

Organizations

Research & Development (54)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Betta Pharmaceuticals Co.,Ltd.For profit413942009
Chinese Academy of Medical SciencesAcademic/Hospital16532009
Zhejiang UniversityAcademic/Hospital10422012
Jiao Tong UniversityAcademic/Hospital8142012
Sun Yat-Sen UniversityAcademic/Hospital8622009
People's Liberation Army of ChinaGovernment5232014
Tianjin Medical UniversityAcademic/Hospital5422012
Peking UniversityAcademic/Hospital3212013
Sichuan UniversityAcademic/Hospital3122011
Southern Medical UniversityAcademic/Hospital3322011
Capital Medical UniversityAcademic/Hospital2012014
Dalian Medical UniversityAcademic/Hospital2112017
Fujian Medical UniversityAcademic/Hospital2112018
Guangxi Medical UniversityAcademic/Hospital2112014
Henan Medical UniversityAcademic/Hospital2222016
Huazhong University of Science and TechnologyAcademic/Hospital2012013
Jiangsu Chia-tai Tianqing Pharmaceutical Co.,LtdFor profit2022018
Shandong UniversityAcademic/Hospital2222014
Tigermed Consulting Co., LtdFor profit2022016
Anhui Medical UniversityAcademic/Hospital1112014
54 organizations
Page 1 / 3